Pengaruh NSAIDS Sebagai Golongan Non-Opiod pada Pasien Gout: Review Literatur
Keywords:
antiinflamasi non steroid (NSAID), gout, non-opioidAbstract
Gout adalah penyakit dengan peradangan akut atau kronis dan kerusakan jaringan yang disebabkan oleh pengendapan kristal monosodium urat (MSU) di sendi tulang, ginjal dan situs subkutan. Obat antiinflamasi nonsteroid (NSAID) termasuk inhibitor selektif siklooksigenase-2 (COX-2) (COXIBs) biasanya di gunakan untuk mengobati asam urat akut. Obat antiinflamasi nonsteroid (NSAID) merupakan kelas obat yang disetujui FDA yang di gunakan sebagai agen antipiretik, antiinflamasi dan analgesik. Untuk mengetahui efikasi dan keamanan obat antiinflamasi non steroid (NSAID) pada gout. Referensi diperoleh melalui tinjauan literatur mengenai obat antiinfalamasi non steroid (NSAID). Pencarian di lakukan melalui database PubMed, NCBI, Journal untuk mengidentifikasi artikel dengan kata kunci “NSAID For Gout”, “Analgesik non-opioid”. Serta dilanjutkan dengan diskusi panel pada kelompok kerja yang terdiri dari seluruh anggota kelompok. Diskusi dan kesepakatan berhasil menyusun topik pembahasan pada golongan non opioid dengan memilih jenis NSAIDs. Melalui data yang diperoleh dari Buku Pedoman Diagnosis dan Pengelolaan GOUT, tata laksana daengan tujuan pencegahan serangan gout akut diberikan selama 6 bulan sejak awal pemberian terapi penurun kadar asam urat dengan menggunakan NSAIDs dosis rendah pada pasien yang mengalami intoleransi atau kontraindikasi kolkisin. Semua pilihan obat untuk menurunkan kadar serum asam urat dimulai dengan dosis rendah dan titrasi dosis meningkat sampai tercapai kadar asam urat <6 mg/dL dan bertahan sepanjang hidup. Untuk menilai tingkat efikas dan keamanan NSAIDs sendiri pada pasien GOUT, tata laksana harus diberikan sesuai dengan Algoritma Rekomendasi Pengelolaan yang dimulai dari pengecekan kadar asam urat serum, dan apabila hasilnya di atas 6 mg /dL, pasien harus memulai terapi pencegahan dengan terapi penurun kadar serum urat.
References
Abhishek A, Roddy E, Doherty M. Gout – a guide for the general and acute physicians. Clinical Medicine. 2017;17(1):54-59.
Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochemical Pharmacology. 2020;180:114147.
Brian W. Coburn T. Treatment Options for Acute Gout [Internet]. PubMed Central (PMC). 2021 [cited 14 July 2021]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366613/
Chaichian Y, Chohan S, Becker M. Long-Term Management of Gout. Rheumatic Disease Clinics of North America. 2014;40(2):357-374.
Cronstein B, Terkeltaub R. Arthritis Research & Therapy. 2006;8(Suppl 1):S3.
Dalbeth N, Choi H, Joosten L, Khanna P, Matsuo H, Perez-Ruiz F et al. Gout. Nature Reviews Disease Primers. 2019;5(1).Marsico F, Paolillo S, Filardi P. NSAIDs and cardiovascular risk. Journal of Cardiovascular Medicine. 2017;18:e40-e43.
Del Favero A. Anti-inflammatory analgesics and drugs used in rheumatoid arthritis and gout. Side Effects of Drugs Annual. 1993;:102-119.
Engel B, Just J, Bleckwenn M, Weckbecker K. Treatment Options for Gout. Deutsches Aerzteblatt Online. 2017;.
García-Rayado G, Navarro M, Lanas A. NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs. Expert Review of Clinical Pharmacology. 2018;11(10):1031-1043.
Ghlichloo I, Gerriets V. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) [Internet]. Ncbi.nlm.nih.gov. 2021 [cited 14 July 2021]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547742/
Gouda A, Beshr E, Almalki F, Halawah H, Taj B, Alnafaei A et al. Arylpropionic acid-derived NSAIDs: New insights on derivatization, anticancer activity and potential mechanism of action. Bioorganic Chemistry. 2019;92:103224.
Grosser T, Ricciotti E, FitzGerald G. The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs. Trends in Pharmacological Sciences. 2017;38(8):733-748.
Kazberuk A, Zareba I, Palka J, Surazynski A. A novel plausible mechanism of NSAIDs-induced apoptosis in cancer cells: the implication of proline oxidase and peroxisome proliferator-activated receptor. Pharmacological Reports. 2020;72(5):1152-1160.
L L. Nonsteroidal anti-inflammatory drug gastropathy [Internet]. PubMed. 2021 [cited 14 July 2021]. Available from: https://pubmed.ncbi.nlm.nih.gov/8803564/
Lucas G, Leitão A, Alencar R, Xavier R, Daher E, Silva Junior G. Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs. Brazilian Journal of Nephrology. 2019;41(1):124-130.
Martinez L, Ekman E, Nakhla N. Perioperative Opioid-sparing Strategies: Utility of Conventional NSAIDs in Adults. Clinical Therapeutics. 2019;41(12):2612-2628.
Oh T, Song I. Long-term opioid use among patients with chronic gout: a cross-sectional study of a sample cohort in South Korea. Clinical Rheumatology. 2020;39(10):3033-3039.
Otani K, Watanabe T, Higashimori A, Nadatani Y, Nagami Y, Taira K et al. Effects of Colchicine on NSAID-Induced Severe Small Intestinal Damage: A Pilot Study. Digestion. 2020;:1-6.
Parolini M. Toxicity of the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) acetylsalicylic acid, paracetamol, diclofenac, ibuprofen and naproxen towards freshwater invertebrates: A review. Science of The Total Environment. 2020;740:140043.
Pedoman Diagnosis dan Pengelolaan Gout. jakarta pusat: Perhimpunan Reumatologi Indonesia; 2018.
Pepine C, Gurbel P. Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view. Clinical Cardiology. 2017;40(12):1352-1356.
Phillips WJ, Currier BL. Farmakologi analgesik: II. Analgesik spesifik. J Am Acad Orthop Surg. 2004 Juli-Agustus; 12 (4): 221-33.
Pillinger M, Mandell B. Therapeutic approaches in the treatment of gout. Seminars in Arthritis and Rheumatism. 2020;50(3):S24-S30.
Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney International. 1993;44(3):643-653.
Seth B. Non-opioid analgesics. Anaesthesia & Intensive Care Medicine. 2019;20(8):456-459.
Sidari A, Hill E. Diagnosis and Treatment of Gout and Pseudogout for Everyday Practice. Primary Care: Clinics in Office Practice. 2018;45(2):213-236.
Steins M, Eschbach C, Villalobos M, Thomas M. Schmerztherapie in der Palliativmedizin. Pneumologie. 2017;71(05):297-306.
Towiwat P, Phungoen P, Tantrawiwat K, Laohakul P, Aiewruengsurat D, Thanadetsuntorn C et al. Quality of gout care in the emergency departments: a multicentre study. BMC Emergency Medicine. 2020;20(1).
Van Durme C, Wechalekar M, Buchbinder R, Schlesinger N, van der Heijde D, Landewé R. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database of Systematic Reviews. 2014
Widiyanto, A., Murti, B., & Soemanto, R. B. (2018). Multilevel analysis on the Socio-Cultural, lifestyle factors, and school environment on the risk of overweight in adolescents, Karanganyar district, central Java. Journal of Epidemiology and Public Health, 3(1), 94-104.
Wu M, Tian Y, Wang Q, Guo C. Gout: a disease involved with complicated immunoinflammatory responses: a narrative review. Clinical Rheumatology. 2020;39(10):2849-2859.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Jurnal Ilmiah Permas: Jurnal Ilmiah STIKES Kendal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.